AU Patent

AU2020239640B2 — Tasimelteon for treating smith-magenis syndrome

Assigned to Vanda Pharmaceuticals Inc · Expires 2020-11-05 · 6y expired

What this patent protects

Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).

USPTO Abstract

Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).

Drugs covered by this patent

Patent Metadata

Patent number: AU2020239640B2
Jurisdiction: AU
Classification: —
Expires: 2020-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.